PMID- 34360736
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 15
DP  - 2021 Jul 26
TI  - Regulatory Macrophages and Tolerogenic Dendritic Cells in Myeloid Regulatory 
      Cell-Based Therapies.
LID - 10.3390/ijms22157970 [doi]
LID - 7970
AB  - Myeloid regulatory cell-based therapy has been shown to be a promising cell-based 
      medicinal approach in organ transplantation and for the treatment of autoimmune 
      diseases, such as type 1 diabetes, rheumatoid arthritis, Crohn's disease and 
      multiple sclerosis. Dendritic cells (DCs) are the most efficient 
      antigen-presenting cells and can naturally acquire tolerogenic properties through 
      a variety of differentiation signals and stimuli. Several subtypes of DCs have 
      been generated using additional agents, including vitamin D3, rapamycin and 
      dexamethasone, or immunosuppressive cytokines, such as interleukin-10 (IL-10) and 
      transforming growth factor-beta (TGF-beta). These cells have been extensively 
      studied in animals and humans to develop clinical-grade tolerogenic (tol)DCs. 
      Regulatory macrophages (Mregs) are another type of protective myeloid cell that 
      provide a tolerogenic environment, and have mainly been studied within the 
      context of research on organ transplantation. This review aims to thoroughly 
      describe the ex vivo generation of tolDCs and Mregs, their mechanism of action, 
      as well as their therapeutic application and assessment in human clinical trials.
FAU - Suuring, Maaike
AU  - Suuring M
AD  - Centre de Recherche en Transplantation et Immunologie-UMR1064, INSERM-ITUN, 
      Nantes Universite, CHU Nantes, 44000 Nantes, France.
FAU - Moreau, Aurelie
AU  - Moreau A
AUID- ORCID: 0000-0002-8519-2632
AD  - Centre de Recherche en Transplantation et Immunologie-UMR1064, INSERM-ITUN, 
      Nantes Universite, CHU Nantes, 44000 Nantes, France.
LA  - eng
GR  - H2020-MSCA-ITN-2019 860003/European Commission/
PT  - Journal Article
PT  - Review
DEP - 20210726
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (IL10 protein, human)
RN  - 0 (Transforming Growth Factor beta)
RN  - 130068-27-8 (Interleukin-10)
RN  - 1C6V77QF41 (Cholecalciferol)
SB  - IM
MH  - Animals
MH  - *Arthritis, Rheumatoid/immunology/therapy
MH  - *Cell- and Tissue-Based Therapy
MH  - Cholecalciferol/pharmacology
MH  - *Dendritic Cells/immunology/transplantation
MH  - *Diabetes Mellitus, Type 1/immunology/therapy
MH  - Humans
MH  - *Immune Tolerance
MH  - Interleukin-10/pharmacology
MH  - *Macrophages/immunology/transplantation
MH  - Transforming Growth Factor beta/pharmacology
PMC - PMC8348814
OTO - NOTNLM
OT  - cell therapy
OT  - clinical trials
OT  - regulatory macrophages
OT  - regulatory myeloid cells
OT  - safety
OT  - tolerogenic dendritic cells
COIS- The authors declare no conflict of interest.
EDAT- 2021/08/08 06:00
MHDA- 2021/09/09 06:00
PMCR- 2021/07/26
CRDT- 2021/08/07 01:07
PHST- 2021/05/31 00:00 [received]
PHST- 2021/07/22 00:00 [revised]
PHST- 2021/07/23 00:00 [accepted]
PHST- 2021/08/07 01:07 [entrez]
PHST- 2021/08/08 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2021/07/26 00:00 [pmc-release]
AID - ijms22157970 [pii]
AID - ijms-22-07970 [pii]
AID - 10.3390/ijms22157970 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Jul 26;22(15):7970. doi: 10.3390/ijms22157970.